PULSE BIOSCIENCES, INC. — Director's Dealing 2023

Mar 24, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pulse Biosciences, Inc. (PLSE)
CIK: 0001625101
Period of Report: 2022-03-17

Reporting Person: Danahy Kevin Patrick (Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-17	Stock Option (right to buy)	$6.41	A	25000	Acquired	2032-02-14	Common Stock (25000)	Direct

Footnotes

F1: On February 14, 2022, the reporting person was granted an option to purchase 150,000 shares of the Issuer's common stock. The option vests upon the achievement of performance objectives, with vesting targets of 25% vesting per year upon achievement of said objectives established by the Issuer's Compensation Committee, subject to the reporting person's continued service through each vesting date. The performance objectives for 2022 were met, resulting in the vesting of the option as to 25,000 shares.